Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BSY001 Safety and PK Study in Healthy Subjects (Phase I)
NCT07377175Phase 1Recruiting
- Sponsor
- China National Biotec Group
- Start
- Aug 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BSY001 in smallpox, cowpox, mpox and 1 more, sponsored by China National Biotec Group. Primary endpoints: Treatment-Emergent Adverse Events (SAD) at 10 days, Laboratory tests (SAD) at Day 10 and 5 more. Started Aug 2025; status: recruiting.
02
Drugs
BSY001
03
Conditions
smallpoxcowpoxmpoxpoxvirus infection
Beyond the preview
Go deeper on NCT07377175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07377175.